Calidi Biotherapeutics closes $6.9M public offering with full over-allotment exercise

Calidi Biotherapeutics, Inc.

Gross proceeds of $6.9M from 1,922,764 common stock units and 1,528,000 pre-funded warrant units.
Each unit priced at $2.00 (common) or $1.999 (pre-funded); Series I warrants exercisable at $2.00 for 5 years.
Underwriters exercised 450,000-unit over-allotment option in full; Ladenburg Thalmann sole book-runner.
Proceeds for working capital, pre-clinical studies, and clinical trial preparation.
Directors and executive officers subject to 90-day lock-up agreements post-closing.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.